Telios Pharma

Exciting News from EyeCRO! We’ve reached a major milestone with our MiDROPS® technology, proving its safety and effectiveness in a Phase II clinical trial by our partner @teliospharma #ARVO2024 businesswire.com/news/home/2024…

Learn about our investigation into a potential treatment of dry eye disease. Experience #EyeGate at #ARVO2024. Booth 1838. #DryEye #DiscoveriesBeyondTheOrdinary

See our vision for the potential future treatment of dry eye disease. Visit #EyeGate at Booth 1838 at #ARVO2024. #DryEye #DiscoveriesBeyondTheOrdinary

Find out how we’re advancing the understanding of dry eye disease. Visit #EyeGate at Booth 1838. #ARVO2024 #DryEye #DiscoveriesBeyondTheOrdinary

#ARVO2024 #eyegate

Peer into the future at #EyeGate. See our latest discoveries in the search for treatment of dry eye disease. Find us at Booth 1838. #ARVO2024. #DryEye #DiscoveriesBeyondTheOrdinary

We’re charting new waters. Visit #EyeGate at Booth 1838 to learn more about a potential new therapy for dry eye disease. #ARVO2024 #DryEye #DiscoveriesBeyondTheOrdinary

See the latest innovation in the search for a therapy that could potentially restore tear function at #EyeGate. Visit us at Booth 1838. #ARVO2024 #DryEye #DiscoveriesBeyondTheOrdinary

Join us in our search for disease modification of dry eye disease. Visit #EyeGate at Booth 1838 to learn more about our science. #ARVO2024 #DryEye #DiscoveriesBeyondTheOrdinary

A sea of change is coming in the potential future of dry eye disease. The #EyeGate is opening at #ARVO2024. Find us at Booth 1838. #DryEye #DiscoveriesBeyondTheOrdinary

Discover what's on the horizon for dry eye disease at #EyeGate. Visit Booth 1838 at #ARVO2024 to find out more. #DryEye #DiscoveriesBeyondTheOrdinary